The risk of metachronous cancers in patients with small-intestinal carcinoid tumors: a US population-based study.

Abstract:

:Small-intestinal carcinoids (SIC) are the most common small-bowel malignancies. We sought to determine the risk of developing SIC before and after other primary malignancies (PM) and the prognosis of patients with SIC, with and without another PM. We used the Surveillance, Epidemiology, and End Results database to identify patients diagnosed with SICs between 1973 and 2007. Multiple primary-standardized incidence ratios were calculated as an approximation of relative risk (RR) to explore the association of SICs with metachronous malignancies. Survival analysis was performed using Kaplan-Meier methods and Cox proportional-hazard models. Among 8331 patients with SICs, 2424 (29%) had another PM at some time. The most common sites were prostate (26.2%), breast (14.3%), colon (9.1%), lung/bronchus (6.3%), and bladder (5.3%). Overall, 67% of patients had a PM diagnosed before SIC (pre-SIC), 33% after SIC (post-SIC), and 8% had a PM both before and after SIC. Among the pre-SIC group, the risk of future SIC was increased after cancers of the small bowel (RR 11.86 (95% CI: 6.13-20.72)), esophagus (4.05 (1.10-10.36)), colon (1.39 (1.05-1.81)), kidney (1.93 (1.12-3.09)), prostate (1.38 (1.17-1.62)), and leukemia (2.15 (1.18-3.61)). Among the post-SIC group, there was an increased risk of future PM of the small bowel (8.78 (4.54-15.34)), liver (2.49 (1.08-4.91)), prostate (1.25 (1.0-1.53)), and thyroid (2.73 (1.10-5.62)). Compared to patients with only SIC, those with a PM pre-SIC had worse mean survival (57.9 vs 40.9 months, HR 1.55 (1.42-1.69), P<0.001). In conclusion, almost one-third of patients with SICs have an associated metachronous primary tumor. When these primaries occur prior to (but not after) the SIC diagnosis, the prognosis is worse than with an initial SIC. The type of malignancies associated with SICs may guide future screening efforts.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

Amin S,Warner RR,Itzkowitz SH,Kim MK

doi

10.1530/ERC-11-0392

subject

Has Abstract

pub_date

2012-05-24 00:00:00

pages

381-7

issue

3

eissn

1351-0088

issn

1479-6821

pii

ERC-11-0392

journal_volume

19

pub_type

杂志文章
  • Perspectives for immunotherapy in endocrine cancer.

    abstract::The fight against cancer has seen major breakthroughs in recent years. More than a decade ago, tyrosine kinase inhibitors targeting constitutively activated signaling cascades within the tumor inaugurated a new era of oncological therapy. Recently, immunotherapy with immune checkpoint inhibitors has started to revolut...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0169

    authors: Latteyer S,Tiedje V,Schilling B,Führer D

    更新日期:2016-10-01 00:00:00

  • Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer.

    abstract::Endocrine therapy has become the most important treatment option for women with estrogen receptor (ER)-positive breast cancer. Urgently needed are prognostic assays that can identify those who need additional adjuvant therapy, such as signal transduction inhibitors or chemotherapy, for ER-positive early breast cancer....

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0078

    authors: Yamashita H,Nishio M,Toyama T,Sugiura H,Kondo N,Kobayashi S,Fujii Y,Iwase H

    更新日期:2008-09-01 00:00:00

  • Peroxisome proliferator-activated receptor gamma and BRCA1.

    abstract::Peroxisome proliferator-activated receptor gamma agonists have been proposed as breast cancer preventives. Individuals who carry a mutated copy of BRCA1, DNA repair-associated gene, are at increased risk for development of breast cancer. Published data in the field suggest there could be interactions between peroxisom...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-18-0449

    authors: Furth PA

    更新日期:2019-02-01 00:00:00

  • Role of hypoxia-inducible factor-1alpha as a cancer therapy target.

    abstract::Hypoxia occurs in solid tumours due to a mismatch between tumour growth and angiogenesis. Hypoxia in solid tumours is associated with an aggressive phenotype and resistance to radiation therapy and chemotherapy leading to poor patient prognosis. Hypoxia-inducible factor-1 (HIF-1) is a transcription factor, which is ac...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.1.01290

    authors: Patiar S,Harris AL

    更新日期:2006-12-01 00:00:00

  • p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer.

    abstract::Administration of the microtubule inhibitor docetaxel is a common treatment for metastatic castration-resistant prostate cancer (mCRPC) and results in prolonged patient overall survival. Usually, after a short period of time chemotherapy resistance emerges and there is urgent need to find new therapeutic targets to ov...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0488

    authors: Gruber M,Ferrone L,Puhr M,Santer FR,Furlan T,Eder IE,Sampson N,Schäfer G,Handle F,Culig Z

    更新日期:2020-03-01 00:00:00

  • Genetically defined mouse models that mimic natural aspects of human prostate cancer development.

    abstract::This review is focused on mouse models for prostate cancer that have been designed on the basis of genetic alterations that are frequently found in human prostate cancer. It begins with an analysis of the similarities and differences in the gross and microscopic anatomy of the mouse and human prostate glands, and exte...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0110225

    authors: Roy-Burman P,Wu H,Powell WC,Hagenkord J,Cohen MB

    更新日期:2004-06-01 00:00:00

  • Circulating microRNAs: macro-utility as markers of prostate cancer?

    abstract::The realization that microRNAs (miRNAs) are frequently deregulated in malignancy has had a major impact on cancer research. In particular, the recent finding that highly stable forms of miRNAs can be accurately measured in body fluids, including blood, has generated considerable excitement. Here, we discuss the potent...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0010

    authors: Selth LA,Tilley WD,Butler LM

    更新日期:2012-06-18 00:00:00

  • Progress in breast cancer chemoprevention.

    abstract::Over the past years there have been significant advances in breast cancer treatment and early detection. For the first time, a decrease in cancer mortality has been observed. Recently, much progress has been made in the understanding of carcinogenesis partly due to available new technologies to detect early molecular ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0090015

    authors: Arun B,Hortobagyi GN

    更新日期:2002-03-01 00:00:00

  • SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.

    abstract::Thyroid cancer is on the rise. Novel approaches are needed to improve the outcome of patients with recurrent and advanced metastatic thyroid cancers. FDA approval of suberoylanilide hydroxamic acid (SAHA; vorinostat), an inhibitor of histone deacetylase, for the treatment of hematological malignancies led to the clini...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0103

    authors: Zhu X,Kim DW,Zhao L,Willingham MC,Cheng SY

    更新日期:2016-07-01 00:00:00

  • Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model.

    abstract::Anaplastic thyroid cancer is one of the most lethal diseases, and a curative therapy does not exist. Doxorubicin, the only drug approved for anaplastic thyroid cancer treatment, has a very low response rate and causes numerous side effects among which cardiotoxicity is the most prominent. Thus, doxorubicin delivery to...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0045

    authors: Marano F,Frairia R,Rinella L,Argenziano M,Bussolati B,Grange C,Mastrocola R,Castellano I,Berta L,Cavalli R,Catalano MG

    更新日期:2017-06-01 00:00:00

  • The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.

    abstract::The destruction of proteins via the ubiquitin-proteasome system is a multi-step, complex process involving polyubiquitination of substrate proteins, followed by proteolytic degradation by the macromolecular 26S proteasome complex. Inhibitors of the proteasome promote the accumulation of proteins that are deleterious t...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-14-0005

    authors: Johnson DE

    更新日期:2015-02-01 00:00:00

  • Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

    abstract::Metastatic duodenopancreatic neuro-endocrine tumors (dpNETs) are the most important disease-related cause of death in patients with multiple endocrine neoplasia type 1 (MEN1). Nonfunctioning pNETs (NF-pNETs) are highly prevalent in MEN1 and clinically heterogeneous. Therefore, management is controversial. Data on prog...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-19-0372

    authors: Sadowski SM,Pieterman CRC,Perrier ND,Triponez F,Valk GD

    更新日期:2020-06-01 00:00:00

  • Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.

    abstract::Pancreatic neuroendocrine tumors (PanNETs) are rare in von Hippel-Lindau disease (VHL) but cause serious morbidity and mortality. Management guidelines for VHL-PanNETs continue to be based on limited evidence, and survival data to guide surgical management are lacking. We established the European-American-Asian-VHL-Pa...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0100

    authors: Krauss T,Ferrara AM,Links TP,Wellner U,Bancos I,Kvachenyuk A,Villar Gómez de Las Heras K,Yukina MY,Petrov R,Bullivant G,von Duecker L,Jadhav S,Ploeckinger U,Welin S,Schalin-Jäntti C,Gimm O,Pfeifer M,Ngeow J,Hasse-Laza

    更新日期:2018-09-01 00:00:00

  • CD74 expression and its therapeutic potential in thyroid carcinoma.

    abstract::CD74, the invariant chain of major histocompatibility complex class II, is also a receptor for macrophage migration inhibitory factor (MIF). CD74 and MIF have been associated with tumor progression and metastasis in hematologic and solid tumors. In this study, we found that 60 and 65% of papillary thyroid cancers were...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0269

    authors: Cheng SP,Liu CL,Chen MJ,Chien MN,Leung CH,Lin CH,Hsu YC,Lee JJ

    更新日期:2015-04-01 00:00:00

  • Current mouse and cell models in prostate cancer research.

    abstract::Mouse models of prostate cancer (PCa) are critical for understanding the biology of PCa initiation, progression, and treatment modalities. Here, we summarize recent advances in PCa mouse models that led to new insights into specific gene functions in PCa. For example, the study of transgenic mice with TMPRSS2/ERG, an ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0285

    authors: Wu X,Gong S,Roy-Burman P,Lee P,Culig Z

    更新日期:2013-06-24 00:00:00

  • MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype.

    abstract::Several lines of evidence indicate that tumorigenesis is a complex multistep process, and that most, if not all, cancers acquire the same set of functional capabilities during development and progression, albeit through various mechanistic strategies. Increasing data show an important role of microRNAs (miRNAs or miRs...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/ERC-09-0222

    authors: Santarpia L,Nicoloso M,Calin GA

    更新日期:2010-01-29 00:00:00

  • Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.

    abstract::Elevated expression of steroid receptor coactivator-3 (SRC-3), a member of the p160 family of nuclear receptor coactivators, has been implicated in tamoxifen resistance of breast tumors while the involvement of the two other members of this family, SRC-1 and SRC-2, is less well characterized. In this study, using smal...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0285

    authors: Karmakar S,Foster EA,Blackmore JK,Smith CL

    更新日期:2010-12-21 00:00:00

  • Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.

    abstract::Vandetanib is an oral tyrosine kinase inhibitor approved for treatment of advanced symptomatic or progressive medullary thyroid cancer (MTC). The current study (Nbib1496313) evaluated the benefit-risk of two starting doses of vandetanib in patients with symptomatic or progressive MTC. Patients were randomized 1:1 to r...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1530/ERC-18-0258

    authors: Hu MI,Elisei R,Dedecjus M,Popovtzer A,Druce M,Kapiteijn E,Pacini F,Locati L,Krajewska J,Weiss R,Gagel RF

    更新日期:2019-02-01 00:00:00

  • microRNA-339-5p modulates Na+/I- symporter-mediated radioiodide uptake.

    abstract::Na(+)/I(-) symporter (NIS)-mediated radioiodide uptake (RAIU) serves as the basis for targeted ablation of thyroid cancer remnants. However, many patients with thyroid cancer have reduced NIS expression/function and hence do not benefit from radioiodine therapy. microRNA (miR) has emerged as a promising therapeutic ta...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0439

    authors: Lakshmanan A,Wojcicka A,Kotlarek M,Zhang X,Jazdzewski K,Jhiang SM

    更新日期:2015-02-01 00:00:00

  • The microbiome in PTEN hamartoma tumor syndrome.

    abstract::Germline PTEN mutations defining PTEN hamartoma tumor syndrome (PHTS) confer heritable predisposition to breast, endometrial, thyroid and other cancers with known age-related risks, but it remains impossible to predict if any individual will develop cancer. In the general population, gut microbial dysbiosis has been l...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0442

    authors: Byrd V,Getz T,Padmanabhan R,Arora H,Eng C

    更新日期:2018-03-01 00:00:00

  • Obestatin stimulates Akt signalling in gastric cancer cells through beta-arrestin-mediated epidermal growth factor receptor transactivation.

    abstract::Obestatin was identified as a gut peptide encoded by the ghrelin gene that interacts with the G protein-coupled receptor, GPR39. In this work, a sequential analysis of its transmembrane signalling pathway has been undertaken to characterize the intracellular mechanisms responsible for Akt activation. The results show ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0192

    authors: Alvarez CJ,Lodeiro M,Theodoropoulou M,Camiña JP,Casanueva FF,Pazos Y

    更新日期:2009-06-01 00:00:00

  • The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

    abstract::Ovarian cancer remains one of the leading causes of cancer deaths. Thus, new biomarkers predictive of response to the standard paclitaxel-carboplatin treatment are needed to improve chemotherapy strategies. MicroRNAs have the potential to modify drug outcomes. Based on this, we have demonstrated in this study that pat...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-10-0148

    authors: Leskelä S,Leandro-García LJ,Mendiola M,Barriuso J,Inglada-Pérez L,Muñoz I,Martínez-Delgado B,Redondo A,de Santiago J,Robledo M,Hardisson D,Rodríguez-Antona C

    更新日期:2010-12-21 00:00:00

  • New drugs for medullary thyroid cancer: new promises?

    abstract::Medullary thyroid cancer (MTC) is a rare tumor arising from the calcitonin-producing parafollicular C cells of the thyroid gland, occurring either sporadically or alternatively in a hereditary form based on germline RET mutations in approximately one-third of cases. Historically, patients with advanced, metastasized M...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0104

    authors: Spitzweg C,Morris JC,Bible KC

    更新日期:2016-06-01 00:00:00

  • Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.

    abstract::Neuroendocrine tumours (NET) of the gastroenteropancreatic system comprise a malignant entity with a low incidence. Only limited information is available on long-term clinical outcome and clinically applicable prognostic factors. We performed a retrospective analysis of a large, well-characterized centre-based patient...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0017

    authors: Pape UF,Berndt U,Müller-Nordhorn J,Böhmig M,Roll S,Koch M,Willich SN,Wiedenmann B

    更新日期:2008-12-01 00:00:00

  • Obesity and cancer: mechanistic insights from transdisciplinary studies.

    abstract::Obesity is associated with a range of health outcomes that are of clinical and public health significance, including cancer. Herein, we summarize epidemiologic and preclinical evidence for an association between obesity and increased risk of breast and prostate cancer incidence and mortality. Moreover, we describe dat...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0400

    authors: Allott EH,Hursting SD

    更新日期:2015-12-01 00:00:00

  • Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue.

    abstract::Parathyroid carcinoma (PaC) is a rare cause of primary hyperparathyroidism. Though the loss of the oncosuppressor CDC73/HRPT2 gene product, parafibromin, has been involved in the hyperparathyroidism-jaw tumor syndrome and in a consistent set of sporadic PaCs, parathyroid carcinogenesis remains obscure. MicroRNAs are a...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0134

    authors: Corbetta S,Vaira V,Guarnieri V,Scillitani A,Eller-Vainicher C,Ferrero S,Vicentini L,Chiodini I,Bisceglia M,Beck-Peccoz P,Bosari S,Spada A

    更新日期:2010-02-18 00:00:00

  • Autophagy in endocrine tumors.

    abstract::Autophagy is an important intracellular process involving the degradation of cytoplasmic components. It is involved in both physiological and pathological conditions, including cancer. The role of autophagy in cancer is described as a 'double-edged sword,' a term that reflects its known participation in tumor suppress...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0042

    authors: Weckman A,Rotondo F,Di Ieva A,Syro LV,Butz H,Cusimano MD,Kovacs K

    更新日期:2015-08-01 00:00:00

  • Role of biomarkers in predicting the occurrence of thyroid neoplasms in radiation-exposed children.

    abstract::With increasing numbers of childhood cancer survivors who were treated with radiation, there is a need to evaluate potential biomarkers that could signal an increased risk of developing thyroid cancer. We aimed to examine the relationships between thyrotropin and thyroglobulin levels and the risk of developing thyroid...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0408

    authors: Shulan JM,Vydro L,Schneider AB,Mihailescu DV

    更新日期:2018-04-01 00:00:00

  • The molecular genetic make-up of male breast cancer.

    abstract::Male breast cancer (MBC) is extremely rare and accounts for less than 1% of all breast malignancies. Therefore, clinical management of MBC is currently guided by research on the disease in females. In this study, DNA obtained from 45 formalin-fixed paraffin-embedded (FFPE) MBCs with and 90 MBCs (52 FFPE and 38 fresh-f...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0278

    authors: Moelans CB,de Ligt J,van der Groep P,Prins P,Besselink NJM,Hoogstraat M,Ter Hoeve ND,Lacle MM,Kornegoor R,van der Pol CC,de Leng WWJ,Barbé E,van der Vegt B,Martens J,Bult P,Smit VTHBM,Koudijs MJ,Nijman IJ,Voest EE,S

    更新日期:2019-10-01 00:00:00

  • Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3.

    abstract::The etiology and pathogenesis of renal cell carcinoma (RCC) are only partially understood. Key findings in hereditary RCC, which may be site specific or a component of a syndrome, have contributed to our current understanding. Important heritable syndromes of RCC are those associated with pheochromocytoma, especially ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0324

    authors: Malinoc A,Sullivan M,Wiech T,Schmid KW,Jilg C,Straeter J,Deger S,Hoffmann MM,Bosse A,Rasp G,Eng C,Neumann HP

    更新日期:2012-05-03 00:00:00